A Meeting Regarding the Therapeutic Potential of Antibodies for HIV
In 2009 Search was introduced to an interesting monoclonal antibody that had been used in a 188 patients in the early days of the disease before the antivirals existed that showed promissing evidence of viral reduction. The antibody is called Cytolin. Since then we have been following the progress of its development as it is now being researched by Dr. Eric Rosenberg at Massachusetts General Hospital. We conducted an interview with Dr. Rosenberg about its progress in October of 2011 which you can read under our Q&A section here. To our surprise in the last few years there has been an explosion of antibodies being approved as therapeutics for all kinds of illnesses, and there are now multiple promising ones in the lab with potential for the HIV population including Ibalizumab, Cytolin, and PRO140.
2010 Letters of Support for High-Impact State Prevention
We spent a lot of 2010 and 2011 doing outreach and education to try and bring advancements in transmisison reduction techniques including the use of chemoprophylaxis and the right to rapid at-home assays to the public ear. In doing so we gained a lot of new friends and continued to win the support of many old friends in the effort towards better, more fair, and more sustainable public health. in the read more section of this full article you will see at the bottom a Download attachment: line after the article where you can download the .pdf's of all of the supporters who aligned with us to help promote highly active prevention, now being called High-Impact Prevention by the CDC. Please review the downloadable letters if you are interested or want to double check on the credibility of our supporters. We are very grateful to all of them for all of the honest and difficult work that they do every day.